Lilly diabetes drug wins backing from EU regulator

A European Medicines Agency panel recommended approving a diabetes drug from Boehringer Ingelheim GmbH and Eli Lilly and Co. that was rejected this month in the United States because of manufacturing deficiencies.

The medicine, Jardiance, should be approved as a treatment for type 2 diabetes, the agency’s Committee for Medicinal Products for Human Use said in a prepared statement Friday. The European Commission usually follows the panel’s advice.

Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.

The Food and Drug Administration said this month it wouldn’t approve the drug until Boehringer fixes the problems disclosed in May after a 2012 inspection of a plant in Ingelheim am Rhein, Germany, where the closely held company is based. The FDA completed its re-inspection of Boehringer’s plant March 7, the company said.

The treatment, also known as empagliflozin, is part of a class of medicines that includes Johnson & Johnson’s Invokana and AstraZeneca Plc’s Forxiga. The drugs help the body get rid of sugar through the kidneys. Type 2 diabetes, the most common kind, is often driven by obesity, as the body loses its ability to process sugar. The disease may be the seventh leading cause of death in the world by 2030, according to the World Health Organization.

 

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.